Kaleido Biosciences ($KLDO)

Stock Image

KLDO Overview

Kaleido Biosciences, a clinical-stage healthcare company, develops microbiome metabolic therapies.The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology.It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions.The company was founded in 2015 and is headquartered in Lexington, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Kaleido Biosciences

Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.